The Quantellect read.As of Nov 19, 2026, 7 active firms cover CorMedix Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $13.00 to $19.00, a moderate spread. The average target of $14.86 sits 230% above the current $4.50. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$14.86
+230.2% upside
Average target across 7 active firms as of Nov 19, 2026 vs $4.50 current
Highest Target$19.00
Average Target$14.86
Lowest Target$13.00
Detailed analyst forecasts for CRMD
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate CRMD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRMD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.06 – $-0.06 · 1 analysts · -114% YoY
Next period, 1 analysts expect CorMedix Inc to earn $-0.06 a share (range $-0.06 – $-0.06), versus $0.43 a year earlier. Full-year consensus is $0.43, growing to $-0.06 the year after.
REVENUE · NEXT QUARTER
$68.2M
Range $68.2M – $68.2M · 1 analysts · -47% YoY
Revenue is expected to reach $68.2M (range $68.2M – $68.2M), -46.5% year-over-year. Full-year consensus is $335.5M, rising to $316.0M next year.
Top analysts covering CorMedix Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRMD.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$14.00+211.1% to target
Overall win rate
52%
+ Follow
#2
Jason Butler
JMP Securities · Rank #62
Buy
$22.00+388.9% to target
Overall win rate
49%
+ Follow
#3
Serge Belanger
Needham · Rank #129
Buy
$15.00+233.3% to target
Overall win rate
46%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #277
Buy
$12.00+166.7% to target
Overall win rate
35%
+ Follow
#5
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$13.00+188.9% to target
Overall win rate
38%
+ Follow
CRMD stock forecast FAQ
What is CRMD's average 12-month price target?+
The 7 active firms with a live target average $14.86 for CorMedix Inc over the next 12 months, ranging from a $19.00 high to a $13.00 low, as of Nov 19, 2026.
Is CRMD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRMD?+
The Street-high target is $19.00 (Citizens), and the Street-low is $13.00 (HC Wainwright & Co.). The average of all 7 active-firm targets is $14.86.
How many active Wall Street firms cover CRMD?+
7 active firms have a recognized rating on CorMedix Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRMD?+
Among analysts who currently cover CRMD, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $14.00 target.
What is CorMedix Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.06 – $-0.06) across 1 analysts. Full-year EPS is projected at $0.43, rising to $-0.06 the following year.
How much revenue is CorMedix Inc expected to report next quarter?+
Consensus revenue is $68.2M (range $68.2M – $68.2M). Full-year revenue is projected at $335.5M, growing to $316.0M next year.
Have analysts been upgrading or downgrading CRMD lately?+
As of Nov 19, 2026, 7 of 7 active firms rate CRMD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.